AMGN — Amgen Inc.

The tape is cautious: AMGN fell 13.7% in the week and 9.3% over the month to $377.35 as of 2026-09-13, pushing RSI to 31.45, even though Q2 2026 revenue rose 10% YoY to $10.1B, non-GAAP EPS hit $6.29, and management raised 2026 guidance. Analysts remain moderately constructive (consensus Buy, average target ~$393), but investors are discounting biosimilar erosion in Prolia/XGEVA and the heavy Horizon-driven debt load.

Revenue has grown from $6.90B in Q3 2023 to $10.05B in Q2 2026, with YoY growth accelerating to 9.7% in Q2 2026 after a slower 5.8% in Q1 2026. Gross margin improved from 61.4% in Q2 2024 to 72.0% in Q2 2026, and operating margin expanded from 22.8% to 35.0% over the same span; Q4 2025 was unusually strong (81.9% gross, 39.8% operating), while net income remains volatile due to acquisition-related charges. Free cash flow is robust at $3.49B in Q2 2026 and ~$10.2B TTM, though legacy Prolia/XGEVA sales fell 33% YoY to $1.1B, offset by 26% growth in six key products.

Fair, with a slight value tilt. As of 2026-09-13, AMGN trades at 23.3x TTM EPS of $16.19 but only ~16.4x next-FY consensus EPS of $23.077, below its 5-year average P/E of 24.66x. PEG TTM is 0.735, dividend yield is 2.26%, and P/S of 5.34 is above the 5-year average of 4.96. The forward multiple looks undemanding if margin expansion persists, but P/B of 17.4 and debt/equity of 4.9 reflect the Horizon balance-sheet burden.

At $377.35, the stock is below the analyst consensus target of $393.17 and recent average of $385.81, suggesting the market is pricing in biosimilar headwinds and pipeline uncertainty rather than the Q2 2026 beat and guidance raise. If Q3 2026 confirms the $23+ forward EPS run-rate and MariTide advances, the forward P/E could re-rate toward 18x (~$415); if Prolia/XGEVA erosion accelerates or MariTide slips, the market may keep the multiple below 16x (~$369). GAAP EPS is noisy ($4.37 in Q2 2026 vs. non-GAAP $6.29), so focus on non-GAAP and FCF.

Oversold but still in a short-term downtrend. As of 2026-09-13, RSI was 31.45, price was 11.3% below its SMA20 and 5.5% below SMA50, though still 5.0% above SMA200. The 1-week return was -13.7% and 1-month -9.3%, versus +6.2% over 3 months. A bounce is possible from oversold levels, but the broken 20/50-day configuration argues for waiting for stabilization above the SMA20 or RSI >40 before adding aggressively; the 200-day line is the key longer-term support.

• Interest-rate path: Amgen's ~$51.9B long-term debt makes debt-service costs and refinancing sensitive to rates, even as stable FCF supports the dividend.
• Drug-pricing and regulatory scrutiny: U.S. and European policy actions on specialty drugs, accelerated approvals, and Medicare negotiation remain overhangs.
• Obesity/metabolic capital flows: Sector enthusiasm is concentrated on obesity, making MariTide's Phase 3 data a major relative-performance driver.
• Biosimilar competition: Prolia/XGEVA erosion shows how quickly legacy blockbusters can face price/volume pressure.
• Healthcare sector rotation: Large-cap biotech has traded defensively in uncertain macro periods, but recent weakness suggests rotation away from the group.

• Q3 2026 earnings in late Oct/early Nov 2026, with guidance updates and commentary on Prolia/XGEVA erosion vs. growth-driver momentum.
• MariTide Phase 3 updates, including extended dosing and head-to-head transition studies, the key long-term obesity optionality.
• Morgan Stanley 24th Annual Global Healthcare Conference in September 2026, where management may discuss commercial execution and pipeline progress.
• European launch/expansion of IMDYLLTRA (tarlatamab) in SCLC after positive Phase 3 overall survival data.
• Potential Repatha and other six key growth drivers sustaining 20%+ growth and offsetting biosimilar losses.

• Heavy leverage: long-term debt of $51.9B and debt/equity of 4.9x from the Horizon acquisition limit financial flexibility and magnify rate risk.
• Biosimilar erosion: Prolia/XGEVA sales fell 33% YoY in Q2 2026; faster-than-expected declines could overwhelm core growth.
• MariTide disappointment or delay: obesity competition is intense, and Phase 3 failure/slow enrollment would remove a major optionality driver.
• Drug-pricing regulation and FDA/EMA scrutiny could pressure pricing, accelerated approvals, or specialty-drug designations.
• GAAP earnings volatility and high P/B (17.4x) mean headline EPS can swing sharply on charges, complicating valuation.

AMGN is a cash-generative, fairly valued large-cap biotech with improving margins and a cheap forward P/E, but the recent 13.7% weekly selloff, heavy debt, and binary MariTide pipeline keep the risk/reward balanced. I would not chase it here; patient investors could accumulate on further weakness or after Q3 confirms the growth trajectory, but this is not a clear buy at $377.35 as of 2026-09-13.

I applied a 17.5x forward P/E to next-FY consensus EPS of $23.077, giving $403.85. This multiple sits between the current ~16.4x forward P/E and the 5-year average TTM P/E of 24.66x, reflecting Amgen's durable FCF, 2.26% dividend, and margin expansion, offset by biosimilar erosion, high leverage, and MariTide pipeline risk.